Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
- Read more about FDA approves New KYPROLIS Combination Regimen With DARZALEX FASPRO and dexamethasone
- Log in or register to post comments
source https://www.pharmatutor.org/content/december-2021/fda-approves-new-kyprolis-combination-regimen-with-darzalex-faspro-and-dexamethasone
No comments:
Post a Comment